Literature DB >> 16386710

Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.

Helen J Knowles1, Robert H te Poele, Robert Te Poole, Paul Workman, Adrian L Harris.   

Abstract

HM74 and HM74a have been identified as receptors for niacin. HM74a mediates the pharmacological anti-lipolytic effects of niacin in adipocytes by reducing intracellular cyclic AMP (cAMP) and inhibiting release of free fatty acids into the circulation. In macrophages, niacin induces peroxisome proliferator-activated receptor gamma (PPARgamma)-dependent and cAMP-dependent expression of genes mediating reverse cholesterol transport, although via an unidentified receptor. We describe constitutive expression of HM74a mRNA and hypoxia- and IFNgamma-inducible expression of HM74 and HM74a in human monocytic cell lines and primary cells in culture. In U937 cells niacin-induced expression of 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), the most potent endogenous ligand of PPARgamma. Both niacin and the structurally distinct HM74/HM74a ligand acifran-induced nuclear expression of PPARgamma protein and enhanced PPARgamma transcriptional activity. Niacin-induced PPARgamma transcriptional activity was pertussis toxin sensitive and required activity of phospholipase A(2) (EC 3.1.1.4), cyclo-oxygenase (EC 1.14.99.1) and prostaglandin D(2) synthase (EC 5.3.99.2). Niacin also induced PPARgamma transcriptional activity in HM74 and HM74a CHO cell transfectants, although not in vector-only control cells. This was sensitive to pertussis toxin and to inhibition of phoshoplipase A(2) and cyclo-oxygenase activity. Additionally, niacin increased intracellular cAMP in U937 via a pertussis toxin and cyclo-oxygenase-sensitive mechanism. These results indicate that HM74 and HM74a can mediate macrophage responses to niacin via activation of the prostaglandin synthesis pathway and induction and activation of PPARgamma. This suggests a novel mechanism(s) mediating the clinical effects of pharmacological doses of niacin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16386710     DOI: 10.1016/j.bcp.2005.11.019

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  32 in total

Review 1.  Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.

Authors:  Insug Kang; Sang-Wook Kim; Jang H Youn
Journal:  J Clin Endocrinol Metab       Date:  2011-08-03       Impact factor: 5.958

2.  Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis.

Authors:  Kashan Ahmed; Sorin Tunaru; Claus-Dieter Langhans; Julien Hanson; Christoph W Michalski; Stefan Kölker; Patricia M Jones; Jürgen G Okun; Stefan Offermanns
Journal:  J Biol Chem       Date:  2009-06-26       Impact factor: 5.157

3.  Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells.

Authors:  Lin-Hua Zhang; Vaijinath S Kamanna; Shobha H Ganji; Xi-Ming Xiong; Moti L Kashyap
Journal:  J Lipid Res       Date:  2012-03-01       Impact factor: 5.922

Review 4.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

5.  Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.

Authors:  Martina Lukasova; Camille Malaval; Andreas Gille; Jukka Kero; Stefan Offermanns
Journal:  J Clin Invest       Date:  2011-02-07       Impact factor: 14.808

6.  Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.

Authors:  Xiaoyu Li; John S Millar; Nicholas Brownell; François Briand; Daniel J Rader
Journal:  Biochem Pharmacol       Date:  2010-07-22       Impact factor: 5.858

7.  Phenylbutyrate induces apoptosis and lipid accumulations via a peroxisome proliferator-activated receptor gamma-dependent pathway.

Authors:  Matthew Milkevitch; Nancy J Beardsley; E James Delikatny
Journal:  NMR Biomed       Date:  2010-06       Impact factor: 4.044

Review 8.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 9.  Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.

Authors:  Helen Vosper
Journal:  Br J Pharmacol       Date:  2009-07-20       Impact factor: 8.739

Review 10.  Nicotinic acid: an old drug with a promising future.

Authors:  E T Bodor; S Offermanns
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.